Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease

Chest

Volumn 130, Issue 1, 2006, Pages 30-36

  Swigris, Jeffrey J ^a   Olson, Amy L ^b   Fischer, Aryeh ^a   Lynch, David A ^a   Cosgrove, Gregory P ^a   Frankel, Stephen K ^a   Meehan, Richard T ^a   Brown, Kevin K ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Connective tissue disease; Interstitial lung disease; Mycophenolate mofetil

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEMORRHAGIC CYSTITIS; HICCUP; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MOUTH ULCER; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCLERODERMA; SJOEGREN SYNDROME; TOTAL LUNG CAPACITY;

EID: 33746372441     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.1.30     Document Type: Article

References (14)

1. Schwarz MI, King T Jr, Raghu G. Approach to the evaluation and diagnosis of interstitial lung disease. In: Schwarz MI, King T Jr, eds. Interstitial lung disease. 4th ed. Hamilton, Ontario: BC Decker, 2003; 1-31
2. Divertie M. Lung involvement in the connective tissue disorders. Med Clin North Am 1964; 48:1015-1030
3. Matthay RA, Schwarz MI, Petty TL. Pleuro-pulmonary manifestations of connective tissue diseases. Clin Notes Respir Dis 1977; 16:3-9
4. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25:549-559
5. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954
6. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136:5-28
7. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis: Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156-1162
8. Nowack R, Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10:1965-1971
9. Schneider C, Gold R, Schafers M, et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002; 25:286-288
10. Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001; 202:341-343
11. Treiber G. Mycophenolate mofetil for therapy-resistant interstitial lung disease associated with ulcerative colitis. Am J Gastroenterol 2000; 95:3674-3675
12. Fischer A, Cosgrove G, Meehan R, et al. Treatment of progressive connective tissue disease-associated interstitial lung disease with mycophenylate mofetil. Arth Rheum 2005; 52:S712-S713
13. Stratton RJ, Wilson H, Black CM. Pilot study of antithymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40:84-88
14. Altschuler EL. Consideration of mycophenolate mofetil for idiopathic pulmonary fibrosis. Med Hypotheses 2001; 57:701-702